GMED vs SNN
Globus Medical vs Smith & Nephew plc — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
SNN
Smith & Nephew plc
59
Watch
| Metric | GMED | SNN |
|---|
| AI Score |
71
|
59
|
| Price |
$85.12
|
$30.05
|
| P/E Ratio |
21.45×
|
19.70×
|
| ROE |
11.8%
|
11.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
68.2%
|
| Debt / Equity |
0.02×
|
0.73×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
75.9
|
40.7
|
| Beta |
0.954
|
0.688
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus SNN.
GMED leads by 12 points.
GMED scores 71/100 (Buy) versus SNN at 59/100 (Watch).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
SNN Committee View
40% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Technical Analyst remains cautious — price structure making lower highs and lower lows. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Dividend yield of 2.7% pays you to wait — Value
- EPS growing 52.3% YoY — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical